Florida Cancer Specialists & Research Institute

Recent papers from Florida Cancer Specialists & Research Institute

1. Post-pandemic Divergent Trends in Firearm Homicide and Suicide Across Demographic and Urbanization Strata in the United States: A National Ecological Study (2018-2024)Cureus · 2026
2. The Perils and Consequences of Payer Step Editing (“Step Therapy”) in U.S. Medical Oncology: Evidence, Case Examples, and Policy RemediesThe Oncologist · 2026
3. Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate CancerJournal of Clinical Oncology · 2026
4. Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian CancerJAMA Oncology · 2026
5. E7386 plus lenvatinib in patients with advanced endometrial cancer that progressed on platinum-based chemotherapy and an anti-PD-(L)1 immunotherapy: a single-arm, open-label, global phase 1b/2 dose-expansion cohortEClinicalMedicine · 2026
6. Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201Gynecologic Oncology · 2026
7. Systematic Review and Meta-Analysis of Hypersensitivity Reactions after High-dose Intravenous IronBlood Advances · 2026
8. Pembrolizumab Plus Chemotherapy for Cervical CancerJAMA Oncology · 2026
9. The Neurobehavioral Profile of Phelan–McDermid Syndrome: Suggestions for Assessment Tools in Light of the 2023 Consensus GuidelinesGenes · 2026
10. Targeting the BAFF and APRIL Pathway in IgA Nephropathy: From Disease Pathogenesis to Clinical Trial EvidenceKidney International Reports · 2026
11. Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular TherapyBiology of Blood and Marrow Transplantation · 2026
12. A Phase II Study to Evaluate the Efficacy of Commercially Available Molecularly Matched Targeted Therapies in the Second-Line SettingThe Oncologist · 2026
13. Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’ESMO Open · 2026
14. 71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trialESMO Open · 2026
15. 48TiP TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancerESMO Open · 2026
16. Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II TrialJournal of Clinical Oncology · 2026
17. Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancerGynecologic Oncology · 2026
18. Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaHemaSphere · 2026
19. Targeting of Wnt–β-Catenin Pathway in Recurrent AmeloblastomaNew England Journal of Medicine · 2026
20. Patterns of Care and Outcomes of Neoadjuvant Chemotherapy or Primary Surgery in Stage III-IV Ovarian Cancer: An Ancillary Study of GOG 262JCO oncology advances. · 2026